Study Reveals BetterLife's LSD Analogue Boosts Structural Neuroplasticity Without Hallucinogenic Side Effects
Study Reveals BetterLife's LSD Analogue Boosts Structural Neuroplasticity Without Hallucinogenic Side Effects
A recent paper has provided new evidence that LSD has outstanding nootropic effects, believed to originate in the drug's neuroplasticity promotion, in both animals and humans. Yet a previous study involving Betterlife's (OTCQB:BETRF) BETR-001 (2-bromo-LSD) similarly demonstrated that, in the treatment of rat embryonic cortical neurons, the drug increases the structural complexity of neurons (dendrite growth and complexity) and therefore generates neural plasticity activity, generally linked to antidepressant effects.
最近的一份論文提供了新的證據 LSD 具有 傑出的促智作用, 被認為起源於藥物的神經可塑性促進, 在動物和人類.然而，以前的研究涉及更好的生活 (OTCQB: BETRF)BETR-001 (2-溴化液化物) 同樣證明，, 在大鼠胚胎皮質神經元的治療, 藥物 增加神經元的結構複雜性 (樹幹生長和複雜性) 並因此產生神經可塑性活性, 通常與抗抑鬱作用有關.
A variety of psychedelic compounds are showing positive signs regarding the treatment of various mental health conditions without hallucinogenic effects, including DMT analogs PSL001 and PSL002 and ibogaine analog MM110.
各種迷幻化合物正在顯示 積極的跡象 關於治療各種精神健康狀況而無致幻影響，包括DMT 類似物 PSL001 和 PSL002 和易泊因模擬 MM110。
BetterLife's study also exhibited certain measurements of structural neuroplasticity in which their proprietary BETR-001 performed better than ketamine.
BetterLife 的研究還展示了對結構神經可塑性的某些測量結構，其中專有的 BETR-001 表現優於氯胺酮。
CEO Ahmad Doroudian said the results "confirm that our proprietary BETR-001, an LSD analog, retains the anti-depressant and neural plasticity activity of LSD without causing hallucination.
首席執行官艾哈邁德·多魯德 結果表示「證實我們專有的 BETR-001，一種 LSD 模擬物，可保留 LSD 的抗抑鬱和神經可塑性活性，而不會引起幻覺。
"The fact that BETR-001 can promote structural plasticity in the prefrontal cortex neurons indicates its therapeutic effects in depression and related disorders, providing a potential patient friendly treatment addressing a very large unmet medical need affecting large number of patients globally," he explained.
他解釋說：「BETR-001 可以促進前額葉皮質神經元中的結構可塑性，這表明其在抑鬱症和相關疾病中的治療作用，從而提供了一種潛在的患者友好治療，以解決影響全球大量患者的非常大量未滿足的醫療需求。」
Preclinical and IND-enabling studies stage BETR-001 is a non-hallucinogenic and non-controlled LSD derivative available for self-administration. Its synthesis patent avoids regulatory hindrances and its pending patent for composition and method of use covers treatment of depression, cluster headaches, PTSD and other neuropsychiatric and neurological conditions.
臨床前和內部啟用研究階段 BETR-001 是一個 可用於自我管理的非致幻和不受控制的 LSD 衍生物。其合成專利避免了監管障礙，其組成和使用方法正在申請的專利涵蓋治療抑鬱症，集群性頭痛，創傷後應激障礙和其他神經精神和神經系統疾病。
The company is also developing BETR-002, a preclinical and IND-enabling studies proprietary compound based on honokiol, the active anxiolytic ingredient of magnolia bark. Its pending patent for method of use and formulations covers treatment of anxiety-related disorders, including benzodiazepine dependence.
該公司也在發展 貝特爾 -002, 基於 honokiol 的臨床前和 IND 啟用研究專有化合物, 該 木蘭樹皮的活性抗焦慮成分。 其使用方法和配方正在申請的專利涵蓋治療焦慮相關疾病，包括苯二氮卓類依賴。
Photo by Milad Fakurian on Unsplash
照片由米拉德·法庫里安在未飛濺
譯文內容由第三人軟體翻譯。